BDNF and Parkinson disease: Therefore, the future treatment of the neurodegeneration of PD may require combination therapy that (a) repairs dystrophic neurons, e.g., with neurotrophin therapy, (b) reduces neuro-inflammation, e.g., with cytokine blocking decoy receptors, and (c) disaggregates α-synuclein, e.g., with monoclonal antibodies targeting domains of α-synuclein.